Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-11
2011-01-11
Harris, Alana M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C436S063000, C436S064000, C436S501000, C436S503000, C436S504000, C436S505000, C436S518000
Reexamination Certificate
active
07867717
ABSTRACT:
Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
REFERENCES:
patent: 5591826 (1997-01-01), de la Chapelle et al.
patent: 5602243 (1997-02-01), Vogelstein
patent: 5650281 (1997-07-01), Vogelstein
patent: 5709998 (1998-01-01), Kinzler et al.
patent: 5837443 (1998-11-01), de la Chapelle et al.
patent: 5922855 (1999-07-01), Liskay et al.
patent: 6048701 (2000-04-01), Kinzler et al.
patent: 6090566 (2000-07-01), Vogelstein et al.
patent: 6191268 (2001-02-01), Liskay et al.
patent: 6538108 (2003-03-01), Liskay et al.
patent: 2003/0224463 (2003-12-01), Liskay et al.
patent: 0 507 852 (1998-04-01), None
patent: WO 91/09964 (1991-07-01), None
patent: WO 95/14085 (1995-05-01), None
patent: WO 95/16793 (1995-06-01), None
Papadopoulos, N. et al. Human Mutation, 10: 89-99, 1997.
Chin et al., “The INK4a/ARF tumor suppressor: one gene—two products—two pathways,”Trends Biochem Sci23(8): 291-296 (Aug. 1998) Abstract.
Eng et al., “Heterogeneous Mutation of the RET Proto-oncogene in Subpopulations of Medullary Thyroid Carcinoma,”Cancer Research, 56: 2167-2170 (May 1, 1996j.
Gruis et al., “Homozygotes for CDKN2(p16) germline mutation in Dutch familial melanoma kindreds,”Nat Genet., 10(3): 351-353 (Jul. 1995) Abstract.
Nagy et al., “Lack of Mutation of the Folliculin Gene in Sporadic Chromophobe Renal Cell Carcinoma and Renal Oncocytoma,”Int. J. Cancer, 109: 472-475 (2004).
Boddrich et al., “Reduced Neurofibromin Content but Normal Gap Activity in a Patient with Neurofibromatosis Type 1 Caused by a Five Base Pair Duplication in Exon 12B of the NF1 Gene,”Biochemical and Biophysical Research Communictions, 214(3): 895-904 (Sep. 25, 1995).
Boehringer-Mannheim, GmBH, “New Detection Methods for the Protein Truncation Test, Nonradioactive (PTT),”Biochemica, 3: 21 (1997).
Boehringer-Mannheim, “More New Products to Meet Your Changing Needs,”Biochemica, 1: 4-5 (1997).
Boehringer-Mannheim, “Protein Truncation Test, Nonreadioactive,” test kit pamphlet Cat. No. 1 888 439 (1997) accompanied by advertisement therefor.
Boman, B.M., “Biologic Functions of the Genes Responsible for Familial Cancer,”Current Opinion in Oncology, 6: 90-95 (1994).
Boman, et al., “Radioimmunoassay of theAPCGene Product Using Antibodies against Its Middle and Carboxyl Regions,”Biochem. Biophys. Res. Comm., 206(3): 909-915 (1995).
Charbonnier et al., “Alternative Splicing ofMLH1Messenger RNA in Human Normal Cells,”Cancer Research, 55: 1839-1841 (May 1, 1995).
Chop et al., “Immunodetection of the Presence or Absence of Full-LengthAPCGene Product in Human Colonic Tissues,”Anticancer Res., 15: 991-998 (1995).
Czech et al., “Proteolytical Processing of Mutated Human Amyloid Precursor Protein in Transgenic Mice,”Molecular Brain Research, 47: 108-116 (1997).
Drummond et al., “Cisplatin and Adriamycin Resistance are Associated with MutL-alpha and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line,”The Journal of Biological Chemistry, 271(33): 19645-19648 (1996).
Hemminki et al., “Loss of the Wild TypeMLH1Gene is a Feature of Hereditary Nonpolyposis Colorectal Cancer,”Nature Genetics, 8: 405-410 (Dec. 1994).
Hogervorst, F.B.L., “The Protein Truncation Test (PTT),”Promega Notes Magazine, 62: 7-14 (1997).
Froggatt et al., “Mutation Screening of MSH2 and MLH1 mRNA in Hereditary Non-Polyposis Colon Cancer Syndrome,”J. Med. Genet., 33: 726-730 (1996).
Kolodner and Alani, “Mismatch Repair and Cancer Susceptibility,”Current Opinion in Biotechnology, 5: 585-594 (1994).
Levy et al., “Inactivation of BothAPCAlleles in Human and Mouse Tumors,”Cancer Res., 54: 5953-5958 (Nov. 15, 1994).
Lynch and Lynch, “25 Years of HNPCC,”Anticancer Research, 14: 1617-1624 (1994).
Lynch et al., “Hereditary Nonpolyposis Colorectal Cancer—Lynch Syndromes I and II,” GastroenterologyClinics of North America, 17(4): 679-712 (Dec. 1988)
Marchuck, D.A., “Genetic Abnormalities in Hereditary Hemorrhagic Telangiectasia,”Current Opinion in Hematology, 5: 332-338 (1998).
Meyers et al., “Cell Cycle Regulation of the Human DNA Mismatch Repair GeneshMSH2, hMLH1andhPMS2,” Cancer Research, 57: 206-208 (Jan. 15, 1997).
Miret et al., “Characterization of a DNA Mismatch-Binding Activity in Yeast Extracts,”The Journal of Biological.Chemistry, 268(5): 3507-3513 (1993).
Mortola and Nasto, “Brown Adipose Tissue and Its Uncoupling Protein in Chronically Hypoxic Rats,”Clinical Science, 93: 349-354 (1997).
Pece et al., “Mutant Endoglin in Hereditary Hemorrhagic Telangiectasia Type 1 Is Transiently Expressed Intracellularly and Is Not a Dominant Negative,”J. Clin. Invest., 100(10): 2568-2579 (Nov. 1997)
Roest et al., “Protein Truncation Test (PTT) to Rapidly Screen the DMD Gene for Translation Terminating Mutations,”Neuromusc. Disord., 3(5/6): 391-394 (1993).
Smith et al., “The APC Gene Product in Normal and Tumor Cells,”PNAS(USA) 90: 2846-2850 (Apr. 1993).
Powell et al., “Molecular Diagnosis of Familial Adenomatous Polyposis,”The New England Journal of Medicine, 329(27): 1982-1987 (Dec. 30, 1993).
Stankovic et al., “ATM Mutations and Phenotypes in Ataxia-Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast Cancer,”Am. J. Hum. Genet., 62: 334-345 (1998).
Tannergard et al., “Mutation Screening in thehMLH1Gene in Swedish Hereditary Non polyposis Colon Cancer Families,”Cancer Research, 55: 6092-6096 (Dec. 15, 1995).
Van Der Luijt et al., “Rapid Detection of Translation-Terminating Mutations at the Adenomatous Polyposis Coli (APC) Gene by Direct Protein Truncation Test,”Genomics, 20: 1-4 (1994).
Wagner et al., “Mutation Detection Using Immobilized Mismatch Binding Protein (MutS),”Nucleic Acids Research, 2319): 3944-3948 (1995).
Wei et al., “Reduced Expression of Mismatch Repair Genes Measured by Multiplex Reverse Transcription-Polymerase Chain Reaction in Human Gliomas,”Cancer Research, 57(9): 1673-1677 (1997).
CA*TX Inc.
Harland Joan C.
Harris Alana M.
Holleran Anne L
Lauder Leona L.
LandOfFree
Immunoassays to detect diseases or disease susceptibility... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoassays to detect diseases or disease susceptibility..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoassays to detect diseases or disease susceptibility... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688753